Press release
CINV Existing and Pipeline Drugs Market Outlook 2031: Expanding from US$ 1.9 Billion to US$ 3.2 Billion with an 5.8% CAGR
CINV Existing and Pipeline Drugs Market
Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=776
Market Dynamics
1. Rising Cancer Prevalence and Chemotherapy Use
Cancer remains one of the leading causes of death worldwide, with millions of new cases diagnosed annually. A significant percentage of cancer patients undergo chemotherapy treatments, which frequently lead to nausea and vomiting, increasing the demand for effective antiemetic therapies.
2. Growing Adoption of Novel CINV Medications
The development of new-generation 5-HT3 receptor antagonists, NK1 receptor antagonists, and Hemp-based antiemetics is improving CINV management. These drugs provide better efficacy, prolonged relief, and fewer side effects, enhancing patient quality of life.
3. Increasing Awareness and Supportive Care Initiatives
Healthcare organizations and pharmaceutical companies are launching awareness campaigns to educate patients and caregivers about CINV prevention and management, leading to a higher adoption of antiemetic treatments.
4. Expansion of Drug Pipelines and Clinical Trials
Several pharmaceutical companies are actively investing in the development of novel antiemetic drugs, leading to a promising pipeline. Clinical trials for combination therapies and long-acting formulations are expected to enhance treatment efficacy in the coming years.
Key Challenges and Restraints
Despite the positive outlook, the market faces several challenges:
High Cost of Newer CINV Medications: Advanced antiemetics can be expensive, limiting access in certain regions.
Side Effects of Antiemetic Drugs: Some patients experience headaches, dizziness, or constipation as side effects.
Regulatory Hurdles: Strict approval processes for new drugs can delay market entry.
Competition from Generic Drugs: Increasing availability of generic antiemetics may impact revenue growth for branded drugs.
Top Manufacturers
GlaxoSmithKline plc
Helsinn Holding S.A.
Heron Therapeutics, Inc.
Merck & Co., Inc.
Tesaro, Inc.
Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=776
Future Trends and Opportunities
Several emerging trends are expected to shape the future of the CINV drugs market:
Development of Long-acting and Combination Therapies: Improving patient compliance and reducing dosing frequency.
Expansion of Hemp-based Treatments: Increasing adoption of medical Hemp for nausea relief.
Advancements in Personalized Medicine: Tailoring antiemetic treatments based on patient genetics and chemotherapy regimens.
Integration of Digital Health Solutions: AI-based platforms for CINV monitoring and management.
Market Segmentation
The CINV existing and pipeline drugs market is segmented based on drug class, distribution channel, and region.
1. By Drug Class
5-HT3 Receptor Antagonists: Ondansetron, Palonosetron, Granisetron.
NK1 Receptor Antagonists: Aprepitant, Fosaprepitant, Rolapitant.
Dopamine Receptor Antagonists: Metoclopramide, Domperidone.
Hemp-based Antiemetics: Dronabinol, Nabilone.
Corticosteroids: Dexamethasone.
2. By Distribution Channel
Hospital Pharmacies: Major distribution channel for prescription antiemetic drugs.
Retail Pharmacies: Increasing accessibility of over-the-counter and prescription CINV drugs.
Online Pharmacies: Rising popularity due to convenience and availability of specialized medications.
3. By Region
North America: Leading market share due to advanced healthcare infrastructure and high chemotherapy rates.
Europe: Growth driven by increasing cancer incidence and robust pharmaceutical R&D.
Asia-Pacific: Rapid expansion due to improving healthcare facilities and rising cancer awareness.
Latin America & Middle East/Africa: Emerging markets with growing demand for CINV treatments.
Conclusion
The global CINV existing and pipeline drugs market is set to grow significantly, driven by increasing cancer prevalence, innovations in antiemetic drug development, and rising awareness about supportive care. While challenges such as high drug costs and regulatory barriers exist, advancements in long-acting therapies, personalized medicine, and digital health integration will continue to drive the market forward. By 2031, improved access to effective CINV treatments will enhance the quality of life for cancer patients globally.
Explore Latest Research Reports by Transparency Market Research:
Pharma 4.0 Market: https://www.pharmiweb.com/press-release/2025-03-18/pharma-40-market-size-will-estimated-to-grow-at-a-cagr-of-177-by-2035-driven-by-digital-transformation-in-drug-manufacturing-exclusive-report-by
Dialysis Equipment Market: https://www.pharmiweb.com/press-release/2025-03-18/dialysis-equipment-market-poised-to-surpass-us-252-bn-by-2035-amidst-rising-ckd-cases-and-technological-advancements-tmr-insights
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact Us:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CINV Existing and Pipeline Drugs Market Outlook 2031: Expanding from US$ 1.9 Billion to US$ 3.2 Billion with an 5.8% CAGR here
News-ID: 3955714 • Views: …
More Releases from Transparency Market Research
Global Monochloroacetic Acid Market Set to Reach USD 1.8 Bn by 2035, Driven by S …
The global Monochloroacetic Acid (MCA) Market is entering a new phase of growth, marked by expanding industrial applications, rising agricultural needs, and notable advancements in pharmaceutical formulations. Valued at US$ 1.1 Bn in 2024, the MCA market continues to gain momentum due to its critical role as an intermediate chemical in the manufacture of herbicides, drugs, and carboxymethyl cellulose (CMC). According to recent industry projections, the market is expected to…
Global Two-Wheeler Navigation Display Market Set to Reach USD 3.5 Bn by 2035, Ex …
The global Two-Wheeler Navigation Display Market is entering a new phase of accelerated growth driven by rapid digitalization, rising motorcycle adoption, and strong demand for advanced rider-assist technologies. According to new industry analysis, the market-valued at US$ 563.3 Mn in 2024-is projected to reach US$ 3.5 Bn by 2035, registering an impressive CAGR of 16.95% during the forecast period (2025-2035).
As two-wheelers continue to dominate mobility across Asia, Europe, and emerging…
Transparent Ceramics Market to Hit USD 8.5 Bn by 2035, Driven by 21.3% CAGR Grow …
The global transparent ceramics market is entering a period of unprecedented expansion, fueled by rising demand in aerospace, defense, consumer electronics, optics, and medical imaging. Valued at US$ 1020.0 Mn in 2024, the market is projected to climb to US$ 8.5 Bn by 2035, registering an exceptional CAGR of 21.3% between 2025 and 2035. Transparent ceramics-recognized for their remarkable optical clarity, mechanical strength, and resistance to extreme temperatures-are emerging as…
Dermatoscope Market Outlook 2035: Global Revenues to Surge from USD 1.0 Billion …
The global Dermatoscope Market is entering a period of accelerated expansion, supported by a growing global emphasis on preventive dermatology, rising skin cancer incidence, and the widespread adoption of advanced imaging technologies. Valued at US$ 1.0 Bn in 2024, the market is projected to grow at a strong CAGR of 11.2% from 2025 to 2035, eventually crossing US$ 3.3 Bn by the end of 2035. This rapid growth reflects increasing…
More Releases for CINV
CINV Treatment Market to Reach USD 3.9 Billion by 2034
Pune, India, November 11, 2025 - The global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market is projected to grow from USD 2.6 billion in 2024 to USD 3.9 billion by 2034, registering a CAGR of 4.1 %, according to Exactitude Consultancy. Rising cancer incidence, increasing chemotherapy adoption, and development of next-generation serotonin (5-HT3) and neurokinin-1 (NK1) receptor antagonists are driving global market expansion.
Download Full PDF Sample Copy of Market Report…
Emerging Trends Influencing The Growth Of The Chemotherapy-Induced Nausea and Vo …
The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Expected to Be by 2034?
There has been a notable growth in the market size of chemotherapy-induced nausea and vomiting (CINV)…
Key Influencer in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market 202 …
How Are the key drivers contributing to the expansion of the chemotherapy-induced nausea and vomiting (cinv) market?
The escalating cases of cancer are expected to foster the expansion of the market for chemotherapy-induced nausea and vomiting (CINV). This rise is due to the uncontrolled development and spread of cancer cells in the body. As cancer prevalence increases, there's an increased drive to produce highly effective and specific anti-emetic treatments, which would…
CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to I …
CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the…
CINV Existing and Pipeline Drugs Market : Growing number of patients undergoing …
The growth of the global chemotherapy induced nausea and vomiting (CINV) market will be steered by the growing number of patients undergoing chemotherapy and a number of new drugs expected to be approved in the near future, says Transparency Market Research. In its report, titled “CINV Existing and Pipeline Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” the business intelligence firm says that…
Global Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs Market Research Re …
This report studies Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering
GlaxoSmithKline Plc
Helsinn Group
Heron Therapeutics
Merck & Co Inc
Tesaro
...
Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of…
